• Home
  • News & Press Releases

News & Press Releases

Press Release

Dear Colleagues, Customers, and Friends,

It has been 43 days.

Forty-three days with thousands of bombs, shells, and missiles fired out at our cities and villages, thousands of destroyed buildings, bridges, streets, thousands of killed people. And there are to be feared thousands of victims yet to come as the war continues with a new focus to the East of our country, the war for democracy to prevail against dictatorship and tyranny, the war of the civilized world against the paranoiac barbarians, the war of good against evil. Russia commits genocide against Ukrainians, terrorizes the population, and engages in looting. Nowadays after the crimes in Chernihiv and Kharkiv, after the massacre in Bucha, Irpin and Borodyanka, everybody understands: the world appears to be once again black and white these days and one can see clearly who stands on the side of Ukraine.

I am thankful to the countries and businesses that support Ukraine. I thank those of you who provide donations and help our refugees, everyone who decided to stop paying taxes and operation in Russia, and everyone who just spreads the truth and makes others aware of it. It is hard to overestimate the importance of knowing and feeling that we are not alone in our fight for freedom.

EnamineThe situation in Kyiv has significantly improved and normalized for the past 2 weeks, so is the west part of our country. We are glad to see that several countries are re-opening their embassies in Kyiv. The president of the European Commission, Ursula von der Leyen, will visit Kyiv in the coming days. This shows optimal level of safety for our employees notably, and that the city returns to normal life. Following the call of our President and Prime minister to resume operations where and when it is possible, in compliance with strict safety regulations ruled by our local authorities, we, Team Enamine including already over 300 chemists, have collectively decided to get back to work in Kyiv. Indeed, gradually, since not all the chemistry can be performed right now, e.g., we avoid performing large-scale synthesis. We also expect some delays with purification and delivery for the first period, being determined to solve these issues as soon as possible with the drastically improving situation. We confirm that a major part of our synthetic operations can be performed, and that our chemists and biologists are ready and motivated to work on your projects and tasks.

Now I personally address these words to you, our valued customers and supporters. Please kindly consider resuming ordering our products and services and let us just do in that manner what we love and are best at: the synthesis. Please help us to restart the work at our full steam on custom synthesis, FTE projects and synthesis of make-on-demand building blocks. We are delighted to continue working with our established customers and are most happy to start new collaborations as we are solicitated.

Continuing ordering our compounds and services is the best support because it allows us to operate and keep our employees, our business and Ukraine strong, beside the other key reason of expediting uniquely your valuable research programs with the Art of Enamine.

Thank you!

Slava Ukraini!

Andrey Tolmachov
Founder and CEO of Enamine

Press Release

Dear Customers, Dear Colleagues, Dear Friends,

The war in our country lasts more than 10 days. We have put on hold most of our operations in Kyiv and ask our customers to wait until this situation is resolved. We thank all of you for your patience. During this time, we have been able to estimate our resources, capabilities, and plan next steps to be done. Now I would like to highlight some of them:

Press Release

Cambridge, England, and Kyiv, Ukraine, December 20, 2021 -- Cambridge Molecular, a leading provider of machine learning and data science services for DNA-Encoded Libraries, announces a collaboration with Enamine, a pioneer in the creation of ultra-large chemical spaces of highly feasible compounds. Enamine is supported by the highly capable IT platform of Chemspace, an online chemical marketplace leader and experienced provider of compound sourcing and procurement services. The partners will apply Cambridge Molecular's deep learning DEL follow-up tool DeepDELve 2 to the world’s largest catalogue of small molecules provided by Chemspace including 20 billion compounds from Enamine’s REAL® Space.

Press Release

Kyiv, Ukraine, 18 October 2021. Several months ago, Prof. Levin and co-workers from University of Chicago developed an elegant method for the “skeletal editing” of organic molecules by nitrogen atom deletion (see Nature 2021, 593, 223–227). Their strategy included the use of an anomeric N-pivaloyloxy-N-alkoxyamide amide as the key reagent. Enamine, the world-leading compound supplier, is proud to announce that this reagent has been just added to the company’s product catalog. The compound is now available from the company’s stock in multigram quantities.

Press Release

Kyiv, Ukraine, June 24, 2021. Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds announced today that it forms a strategic alliance with Chemspace, an online marketplace leader for small molecules, and will use the company as its exclusive aggregator platform to supply worldwide all its catalogue products starting from January 1, 2022. Chemspace will be the only online commercial resource in the world that will enable accessing and searching all Enamine’s catalogs. Enamine will continue direct supplies to the drug discovery community and at the same time will cease its historical collaborations with all other compound aggregator platforms.


Press Release

The company's expansion in the biological assay space aided by the data platform

SAN FRANCISCO and KYIV, Ukraine, June 10, 2021 - Enamine, a leading provider of R&D Services as well as Screening Compounds, Fragments, Building Blocks and specialized libraries for Drug Discovery, announced today that it had implemented Collaborative Drug Discovery's CDD Vault to manage its biological assay data. The platform will enable seamless and secure exchange of information between Enamine and its partners in pharmaceuticals, biotechs and other organizations conducting drug discovery research.


News

We are happy to announce the start of Project ALISE supported by European Commission under Horizon 2020 MSCA-RISE. As the coordinator of the Project, Enamine is involved in the development of light-controllable antibody peptide conjugates pushing the boundaries of photopharmacology towards clinical applications.

News

We have several Postdoc positions in organic chemistry to work at Enamine Ltd. (Ukraine, Kyiv) on a ERC-project “Saturated bioisosteres of benzene.” Start: 1 April 2021 (or later).

Please, send the application documents (motivation letter, CV, list of publications, recommendation letters) to This email address is being protected from spambots. You need JavaScript enabled to view it.

News

Enamine will provide chemical synthesis support for a global nonprofit research initiative OpenPandemics COVID-19, organized by Scripps Research and IBM, and aimed at rapidly identifying efficient new drugs against the coronavirus SARS-CoV-2. Enamine will be synthesizing any promising hits identified by the research team at OpenPandemics COVID-19 via large scale docking experiments.

News

Call for Donations

We, at Enamine, have united to resist at our level the Russian invasion. We help to acquire non-lethal military aid to enhance defence of Ukraine, provide medical supplies to the hospitals, provide sponsorship for science and education in Ukraine, and help our employees scattered by war across Ukraine and abroad. Our own funds are limited as we have had to put on hold most of our projects and we will greatly appreciate your donations, which we will immediately use for the urgent needs of today! This is the most direct help to Ukraine.

Please use correct currency accounts and indicate the purpose of payment as “charitable assistance”.

In order to track your donation please inform us about it by email: This email address is being protected from spambots. You need JavaScript enabled to view it.. If you have any particular purpose of donation (e.g. “medicines”, “social help”) please indicate it in your email. Please also contact us by email if you have any questions about the fund.

Thank you for your support!

USD Account

Company name: ENAMINE СF
Addrеss: 78 CHERVONOTKATSKA STR., KYIV, 02094, UKRAINE
IBAN (USD):UA823052990000026001030119037
Bank: JSC CВ PRIVATBANK
Bank adress: 1D HRUSHEVSKOHO STR., KYIV, 01001, UKRAINE
SWIFT · BIC: PBANUA2XXXX

Соrrеsроndеnt bank: JP Моrgаn Chase Ваnk, New Yоrk, USA
Account in the соrrеsроndеnt bаnk: 001-1-000080
SWIFT Code of the соrrеsроndеnt bank: CHASUS33

рurроsе of payment: "charitable assistance"

EUR Account

GBP Account

CHF Account

Press Release

Kyiv, Ukraine, 22 November 2021. Recently, Prof. Magolan and coworkers from McMaster University (Hamilton, Ontario, Canada) reported that hexafluoroisopropyl sulfamate (HFIPS) is a convenient reagent for the sulfamoylation of alcohols and amines (Org. Lett. 2021, 23, 3373–3378). HFIPS has also been used for metal-catalyzed C–H aminations (J. Am. Chem. Soc. 2014, 136, 5783–5789) and for the synthesis of aziridines using silver catalysis (Synthesis 2018, 50, 4462–4470) or electrochemical conditions (Angew. Chem. Int. Ed. 2018, 57, 5695–5698). Enamine has adapted and scaled-up the published procedure to synthesize HFIPS and make it more accessible to scientists worldwide. The reagent is now available in Enamine’s catalogue in multigram quantities.

News

We are proud to announce that our covalent compound library is now available in a ready-to-dock format for BioSolveIT’s drug design dashboard SeeSAR. Over 20 different warheads were processed and translated to their respective ligand-bound form to assess their binding mode after docking.

News

We still have several funded Postdoc positions in organic chemistry to work at Enamine Ltd. (Ukraine, Kyiv) on a ERC-project “Saturated bioisosteres of benzene.”

Start: any time.
Please, send the application documents (motivation letter, CV, list of publications, recommendation letters) to This email address is being protected from spambots. You need JavaScript enabled to view it.

Press Release

A new multi-year drug discovery agreement will focus on CNS drug discovery

Kyiv, Ukraine, February 24 2021 - Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’ small molecule CNS drug discovery programs.


News

Congratulations to Pavel Mykhailiuk, Chief Scientific Officer at Enamine, for receiving ERC Consolidator Grant funding for the Project: BENOVELTY - Saturated bioisosteres of benzene and their application in drug design.

The research will be carried out at Enamine Ltd in Ukraine, a global provider of chemical and biological services to biotech companies, academic institutions and research organisations.

Press Release

Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), has joined the Advanced Machine Learning for Innovative Drug Discovery (AIDD) program, funded by the European Union within the framework of the Marie-Skłodowska-Curie Actions (MSCA) with a budget of Euros 3.93 million. The project, coordinated by Helmholtz Zentrum München,Germany, brings together fifteen institutions from eleven countries in addition to the University of British Columbia (Canada) to train sixteen PhD students in close collaboration with associated partners from the USA, Australia, China, Israel and other countries and develop next generation AI and Machine Learning (ML) models and systems for drug discovery.


FOLLOW US